Alpha Tau to Join May 2024 Investor Conferences

Alpha Tau Medical Ltd., a trailblazing Israeli medical device company specializing in the innovative alpha-radiation cancer therapy known as Alpha DaRT, has announced that its Chief Financial Officer, Raphi Levy, will participate in two significant investor conferences in May 2024.

The first event is the Guggenheim Securities Radiopharmaceuticals Day, where Levy will give a presentation on May 13, 2024, at 11:30 AM ET, in New York, NY. The second event is the H.C. Wainwright 2nd Annual BioConnect Investor Conference. At this event, Levy will engage in a Fireside Chat scheduled for May 20, 2024, at 2 PM ET, also in New York, NY. During these conferences, Levy will also be available for one-on-one meetings with investors. Interested parties are encouraged to contact their respective Guggenheim Securities and H.C. Wainwright representatives to arrange these meetings.

Alpha Tau Medical Ltd. was founded in 2016 and has since dedicated itself to the research, development, and potential commercialization of its proprietary Alpha DaRT technology. The company’s core innovation, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), was originally developed by Professors Itzhak Kelson and Yona Keisari from Tel Aviv University. This advanced therapy aims to provide potent and targeted treatment of solid tumors through the intratumoral delivery of radium-224 impregnated sources.

The functioning of Alpha DaRT is based on the decay properties of radium-224. When the radium decays, it releases short-lived daughter isotopes that emit high-energy alpha particles. These particles are aimed at destroying cancerous cells within the tumor. Due to the limited diffusion range of the alpha-emitting atoms, the therapy is designed to primarily target the tumor itself while sparing the surrounding healthy tissue from radiation exposure. This targeted approach holds the potential for a highly effective cancer treatment with reduced side effects compared to traditional radiation therapies.

Alpha Tau's participation in these investor conferences signifies a critical opportunity for the company to present its groundbreaking work to potential investors and stakeholders. This engagement not only highlights the company's innovative approach to cancer treatment but also opens up avenues for further investment and collaboration.

Alpha Tau's Alpha DaRT technology represents a significant advancement in the field of oncology, particularly in the treatment of solid tumors. The company’s commitment to developing and commercializing this technology is rooted in its mission to improve cancer treatment outcomes while minimizing harm to patients.

With its headquarters in Jerusalem, Alpha Tau continues to push the boundaries of medical science, striving to bring its cutting-edge Alpha DaRT therapy to the forefront of cancer treatment options. The upcoming investor conferences in May 2024 offer a platform for Alpha Tau to share its progress, garner support, and attract potential investors who are keen to be part of the future of cancer therapy.